CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo
Fig 3
CC-223 blocks mTORC1 and mTORC2 activation in HCC cells.
HepG2 cells, the primary human HCC cells (“HCC1” line) or the L02 normal hepatocytes were treated with designated concentration of CC-223 (10–1000 nM), cells were further cultivated in conditional medium for indicated time; Expression of listed proteins was tested (A-C). HepG2 cells were also treated with 500 nM of RAD001 or rapamycin, cell viability (CCK-8 assay, D) and apoptosis (TUNEL assay, E) were tested. # p <0.05 vs. “CC-223” (D and E).